Stock analysts at Oppenheimer assumed coverage on shares of Motus GI (NASDAQ:MOTS) in a research note issued to investors on Monday. The brokerage set an “outperform” rating and a $7.00 price target on the stock. Oppenheimer’s price target would suggest a potential upside of 46.14% from the stock’s previous close.
Separately, Piper Jaffray Companies assumed coverage on Motus GI in a report on Sunday. They set an “overweight” rating and a $7.00 price target for the company.
Shares of Motus GI (NASDAQ:MOTS) opened at $4.79 on Monday. The stock has a market capitalization of $73.19 and a PE ratio of -6.39. Motus GI has a fifty-two week low of $3.75 and a fifty-two week high of $5.30.
ILLEGAL ACTIVITY WARNING: This news story was reported by Markets Daily and is the sole property of of Markets Daily. If you are viewing this news story on another site, it was illegally copied and reposted in violation of U.S. and international trademark and copyright legislation. The correct version of this news story can be accessed at https://www.themarketsdaily.com/2018/03/14/motus-gi-mots-now-covered-by-analysts-at-oppenheimer.html.
Motus GI Company Profile
Motus GI Holdings, Inc is a medical technology company. The Company is developing Pure-Vu system that integrates with existing colonoscopes to cleanse poorly prepped colons during the colonoscopy procedure. The Pure-Vu system uses a precise mixture of water and air to loosen debris from the colon mucosa while simultaneously evacuating the bowel contents, clearing the way for the endoscopist to perform a high quality examination, even when the patient is not fully clean prior to their procedure.
Receive News & Ratings for Motus GI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Motus GI and related companies with MarketBeat.com's FREE daily email newsletter.